Infectious Diseases 2021

Infectious Diseases 2021

EU: Antimicrobial Resistance in zoonotic bacteria 2018-19

20 April, 2021

Data on antimicrobial resistance (AMR) in zoonotic and indicator bacteria from humans, animals and food are collected annually by the EU Member States (MSs), jointly analysed by the EFSA and the ECDC and reported in a yearly EU Summary Report. 
A sizeable proportion of Salmonella and Campylobacter bacteria is still resistant to antibiotics commonly used in humans and animals, as in previous years, says a report released by the European Centre for Disease Prevention and Control (ECDC) and the European Food Safety Authority (EFSA). In humans, high proportions of resistance to ciprofloxacin, an antibiotic commonly used to treat several types of infections, were reported in a specific Salmonella type known as S. Kentucky (82.1%). In recent years, S. Enteritidis resistant to nalidixic acid and/or ciprofloxacin has been increasingly reported in several countries. The increasing occurrence of fluoroquinolone and/or quinolone resistance in these types of Salmonella probably reflects the spread of particularly resistant strains. In Campylobacter, resistance to ciprofloxacin is now so common in most countries that this antimicrobial has limited use in treatment of Campylobacter infections in humans. However, the report also includes some positive findings. Over the period 2015-2019, a decline in resistance to ampicillin and tetracyclines has been observed in Salmonella isolates from humans in eight and eleven Member States respectively. Combined resistance to two critically important antimicrobials – fluoroquinolones and third generation cephalosporines in Salmonella and fluoroquinolones and macrolides in Campylobacter – remains low. These critically important antimicrobials are commonly used to treat serious infections from Salmonella and Campylobacter in humans. The report was based on antimicrobial resistance monitoring data collected by Member States as part of their EU regulatory obligations and jointly analysed by EFSA and ECDC with the assistance of external contractors.